Clinical Investigation

You have free access to this content

Evaluation of Rosiglitazone Administration on Cardiovascular Function in Severe Obesity

  1. Amelia Brunani MD1,*,
  2. Antonio Liuzzi MD1,
  3. AnnaMaria Titon MD2,
  4. Salvatore Graci MD1,
  5. Giovanna Castagna PhD3,
  6. Gian Carlo Viberti MD4,
  7. Luca A. Gondoni MD2

Article first published online: 18 DEC 2008

DOI: 10.1002/clc.20339

Issue

Clinical Cardiology

Clinical Cardiology

Volume 31, Issue 12, pages 602–606, December 2008

Additional Information

How to Cite

Brunani, A., Liuzzi, A., Titon, A., Graci, S., Castagna, G., Viberti, G. C. and Gondoni, L. A. (2008), Evaluation of Rosiglitazone Administration on Cardiovascular Function in Severe Obesity. Clin Cardiol, 31: 602–606. doi: 10.1002/clc.20339

Author Information

  1. 1

    Department of Internal Medicine

  2. 2

    Unit of Cardiac Rehabilitation

  3. 3

    Laboratory Ospedale San Giuseppe, IRCCS, Istituto Auxologico Italiano, Verbania, Italy

  4. 4

    Department of Diabetes and Endocrinology, GKT School of Medicine, Guy's Hospital, King's College of London, London, United Kingdom

*Ospedale San Giuseppe Piancavallo 28900 Verbania, Italy

Publication History

  1. Issue published online: 18 DEC 2008
  2. Article first published online: 18 DEC 2008
  3. Manuscript Accepted: 2 NOV 2007
  4. Manuscript Received: 19 SEP 2007

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (105K)

References

  • 1
    Hirayama H, Sugano M, Abe N, Yonemoch H, Makino N: Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients. Int J Cardiol 2001; 77: 75–79.
  • 2
    Martens FM, Visseren FL, Lemay J, de Konong EJ, Rabelink TJ: Metabolic and additional vascular effects of thiazolinediones. Drugs 2002; 62: 1463–1480.
  • 3
    Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 1–15.
  • 4
    Hollenberg NK: Considerations for management of fluid dynamic issues associated with thiazolinediones. Am J Med 2003; 115(Suppl 8A): 111S–115S.
  • 5
    Peterson RL, Waggoner AD, Schetchman KB, Meyer T, Gropler RJ, et al.: Alterations in left ventricular structure and function in young healthy obese women. J Am Coll Cardiol 2004; 43: 1399–1404.
  • 6
    Piccoli A, Brunani A, Savia G, Pillon L, Favaro E et al.: Discriminating between body fat and fluid overload changes in the obese adults using bioimpedance vector analysis. Int J Obes 1998; 22: 97–104.
  • 7
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA Teacher DF, et al.: Homeostasis model assessment, insulin resistance and ß cell function from fasting plasma glucose and insulin concentration in human. Diabetologia 1985; 28: 412–419.
  • 8
    Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613–618.
  • 9
    Sutton MSJ, Rendell M, Dandona P, Dole JF, Murphy K, et al.: Rosiglitazone clinical trias study froup. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058–2064.
  • 10
    Kiryluk K, Isom R: Thiazolidinediones and fluid retention. Kidney Int 2007; 72: 762–768.
  • 11
    Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, et al.: Thiazolidinediones use, fluid retention and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941–1948.
  • 12
    Kim SH, Abbassi F, Chu JW, McLaughlin TL, Lamendola C, et al.: Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 2005; 54: 2447–2452.
  • 13
    Avandia (rosiglitazone maleate) tablets: prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2007 (package insert).
  • 14
    Sotiropoulos KB, Clermont A, Yasuda Y, Rask-Madsen C, Mastumoto M et al. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J 2006; 20: 1203–1205.
  • 15
    Pickavence LC, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JPH: Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol 1999; 128: 1570–1576.
    Direct Link:
  • 16
    Rennings AJM, Smits P, Stewart MW, Tack CJ. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care 2006; 29: 581–587.
  • 17
    Sarafidis PA, Nilsson PM: The effects of thiazolidinediones on blood pressure levels—a systemic review. Blood Press 2006; 15: 135–150.
  • 18
    Amà R, Segers P, Roosens C, Claessens T, Verdonck P, et al.: The effects of load on systolic mitral annular velocity by tissue Doppler imaging. Anesth Analg 2004; 99: 332–338.
  • 19
    Gondoni LA, Titon AM, Silvestri G, Nibbio F, Taronna O, et al.: Short term effects of physical exercise and low calorie diet on left ventricular function in obese subjects: a tissue Doppler study. Nutr Metab Cardiovasc Dis 2007; 17: 358–364.
  • 20
    Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Matthew WR, et al.: Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005; 146: 5341–5349.
  • 21
    Kelly AS, Bank AJ: The cardiovascular effects of the thiazolidinediones: a review of the clinical data. J Diabetes Complications 2007; 21: 326–334.
Get PDF (105K)